Keywords: fda, gives, priority, review, novartis, femara, new

US FDA gives priority review to Novartis' Femara in new indication

Article | 05 September 2005

Print This

The US Food and Drug Administration has granted priority review to Swiss drug major Novartis' Femara (letrozole), a once-daily aromatase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in